COMPARE · Data as of August 28, 2026
CNS vs HLNE
Verdict: Side-by-side breakdown using the Bull Rankings model. CNS scored 74.0, HLNE scored 78.0 — HLNE leads.
Compare another set
Different reporting periods. HLNE's fundamentals are as of June 2026, but CNS's are as of March 2026 — a 3-month gap. Growth, margin and valuation figures below therefore describe different windows and aren't strictly like-for-like.
CNS
Cohen & Steers, Inc.
71.6Fin
$82.63 · $4.2B
fundamentals as of
Strength gap
8.0
HLNE leads
HLNE
Hamilton Lane Incorporated
79.6Fin
$106.04 · $5.9B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- CheapestHLNE16.1x
- Fastest growthCNS+7.7%
Side by side · every name on one set of axes
Growth against the P/E multiple. Up and to the right is cheaper and faster — the quality-growth idea in one picture. Points beyond the axis are pinned to the edge and marked off-scale rather than allowed to compress everything else.
Fundamentals, head-to-head
CNS
HLNE
+7.7%B
Rev
+6.5%C+
25.7xC
P/E
16.1xC+
27.3%A-
ROE
32.4%A
7.21D
P/B
4.84D
3.2%B
Yield
2.2%B
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
The companies
CNSCohen & Steers, Inc.
Why now
Asset Management · market cap $4.2b. 5% off the 52-week high of $86.56. 3 sell-side analysts rate this a Hold with a mean 1-yr target of $76.00 (implying -8% upside).
Moat
Net margin 29% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 27% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which.
Risk
Balance-sheet financial — book value, net interest margin, and credit loss provisions are the lever points; a rates regime change or a deterioration in the loan book moves the stock more than EPS does.
HLNEHamilton Lane Incorporated
Why now
Asset Management · market cap $5.9b. Down 32% from 52-week high of $155.66 — deep drawdown territory. 7 sell-side analysts publish a mean 1-yr target of $133.57 (implying +26% upside).
Moat
Net margin 32% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 32% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which.
Risk
Down 32% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Balance-sheet financial — book value, net interest margin, and credit loss provisions are the lever points; a rates regime change or a deterioration in the loan book moves the stock more than EPS does.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.